Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3503859 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP1A2CYP2D6PKMNPSR1 | |
| SCHEMBL1171628 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP1A2CYP2D6PKMNPSR1 | |
| SCHEMBL21883931 | 0.83 | NPSR1 (0.43) | SMN1; SMN2CYP1A2CYP2D6NPSR1KMT2A | |
| SCHEMBL13168126 | 0.82 | PTGS2 (0.44) | SMN1; SMN2CYP1A2CYP2D6PKMNPSR1 | |
| SCHEMBL9601863 | 0.82 | ALDH1A1 (0.53) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL28883413 | 0.82 | CA12 (0.53) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL11244962 | 0.81 | CA12 (0.57) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL11244967 | 0.81 | CA12 (0.57) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL11385770 | 0.81 | CA12 (0.57) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL23489143 | 0.79 | ALDH1A1 (0.41) | SMN1; SMN2CYP1A2CYP2D6PKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| CN-116194144-A | Prodrugs of phosphoramide nucleotide analogs and pharmaceutical uses thereof | 吉利德科学公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11357828-B2 | Releasable GLP-1 conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | CA12 2235/4885CA1 2620/4885CA2 3860/4885 |
| US-11357828-B2 | Releasable GLP-1 conjugates | GLP1R, GIPR, IAPP | CA12 4413/4885CA1 3398/4885CA2 4467/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | CA12 2235/4885CA1 2620/4885CA2 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.